UPS Pours $48M into 27 Global Cold-Chain Facilities to Support GLP-1 Drugs
UPS•UPS is investing $48 million to build out 27 temperature-controlled cross-dock facilities across the Americas, Europe and Asia to support refrigerated pharmaceuticals such as GLP-1 weight-loss drugs. The healthcare division surpassed $3 billion in first-quarter revenue as UPS shifts toward higher-margin cold-chain logistics.
1. $48 Million Cold-Chain Expansion
UPS is deploying $48 million to build 27 temperature-controlled cross-dock facilities spanning North and South America, Europe and Asia. These sites will enhance end-to-end cold-chain capacity for pharmaceuticals requiring strict refrigeration throughout transit.
2. Surge Driven by Refrigerated Pharmaceuticals
Demand for GLP-1 weight-loss drugs such as Wegovy and Ozempic, which must remain refrigerated, is a primary driver of this investment. The temperature-sensitive biologics market is forecast to expand at an 8.3% CAGR to $39.1 billion by 2033.
3. Healthcare as Strategic Growth Pillar
UPS’s healthcare unit has grown its market share annually since 2021, clearing $3 billion in revenue in Q1 2026. The company has also bolstered its footprint through acquisitions like Andlauer Healthcare Group, aligning with a shift toward higher-margin logistics services.
Related News
Sources
UPS invests $48 million in cold-chain healthcare logistics
Finance
UPS is spending $48 million to keep up with the GLP-1 boom. The drugs that need refrigeration are reshaping logistics
Qz
